• Skip to main content
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Animal models and their alternatives share the preclinical habitat – Transition from in vivo models to NAMs

August 1, 2024

Resource > Articles >

Animal models and their alternatives share the preclinical habitat – Transition from in vivo models to NAMs

Filed under: ADME, Disease modeling, and Safety toxicology

cnb1435 gen animal models alternatives tmb v1 | transition from in vivo models to NAMs
View full article

Originally published in Genetic Engineering & Biotechnology News on 1 August 2024.

Animal models are important tools that are extensively leveraged in preclinical drug testing. They have long been established as the gold standard for safety and efficacy testing, especially for small molecule based therapeutics.

However, in recent years there has been a significant push for integrating New Alternate Methodologies (NAMs) such as microphysiological systems (MPS), also known as Organ-on-a-chip (OOC) models into the drug development pipeline – a transition from in vivo models to NAMs. Not only do these “humanized” models better reflect human response but also allows a reduction in animal use – focusing on responsible and ethical use of these models. This aligns with the animal welfare principles known as the “3Rs”: reduction, replacement, and refinement. An alternative set of principles, the “4Rs,” adds another “R”: responsibility. Whichever set of “Rs” is applied, the idea is to solve ethical problems in functional animal experimentation.

Meanwhile, the FDA Modernization Act 2.0 challenges the entrenchment of in vivo animal models in preclinical work and supports development of alternative models. Another piece of legislation, the Biosecure Act, if passed, will significantly impact the sources U.S. researchers use to obtain their animal models.

In response to these shifts, the preclinical landscape is undergoing a transformation. Traditional animal models continue to play an important role, particularly genetically defined and immuno-humanized mice, but there is increasing integration of advanced in vitro systems. Charles River Laboratories has committed hundreds of millions to developing NAMs, including in vitro and in silico tools, while also introducing innovations like the PathogenBinder test that reduces reliance on sentinel animals.

Dr. Emily Richardson, Lead Scientist of Toxicology at CN Bio emphasized that the PhysioMimix® Organ-on-a-chip System supported a successful 2023 regulatory submission for a liver disease candidate, illustrating the regulatory traction of MPS platforms.

“CN Bio recently secured $21 million in Series B investment to expand their design and manufacture of 3D human organ and tissue microphysiological systems (MPSs). The company’s PhysioMimix OOC Higher Throughput System and associated Multi-chip Liver-48 plate was developed in response to market demand. The new plate features a standard SLAS-footprint with 48 miniaturized chips. Three plates can be run simultaneously.

“Importantly, supporting data from the PhysioMimix platform were incorporated into a successful 2023 regulatory submission,” says Richardson. “Inipharm’s INI-822 for a common fibrotic disorder is now in clinical trials. Plus, collaborators at Charles River developed and published a novel genotoxicity application using the system.”

CN Bio also launched a primary gut/liver dual-organ model for improved human ADME and bioavailability estimations. The model was developed with Altis Biosystems, which recreated the intestinal barrier using primary cells isolated from the human jejunum on a biomimetic scaffold (RepliGut). When connected to the Liver-on-a-chip model in the Multi-chip Dual-organ plate, an improved predictive capacity for profiling the ADME behavior of oral drugs was seen as compared to an equivalent Caco-2 Gut/Liver MPS

A Gut/Liver MPS for profiling human oral bioavailability

Webinar on demand

A Gut/Liver MPS for profiling human oral bioavailability

Dr. Yassen Abbas and  Dr. Elizabeth Boazak (Altis Biosystems) discuss how the fluidically-linked gut and liver models enable more accurate modeling of oral bioavailability.
Watch here

“We are expanding our range of all-in-one kits – (NASH in a box, Bioavailability assay kit: Human 18, DILI assay kit: Human 24 )” Richardson asserts. “The kit contains everything required to recreate our models and applications, and to develop preclinical animal MPS models to flag potential interspecies differences and minimize the risk of unforeseen clinical issues.” Initial results demonstrate the translatability of animal MPS data.

Picture1 | transition from in vivo models to NAMs

This image depicts MASH liver tissue, showcasing the fibrotic phenotype (yellow) associated with the disease. The tissue is composed of primary human hepatocytes, Kupffer cells, and stellate cells. To help researchers model Metabolic dysfunction-associated steatohepatitis (MASH), also known as non alcoholic steatohepatitis (NASH), CN Bio provides the NASH-in-a-box, a modeling kit that is compatible with the both the Single-organ and Multi-organ versions of the company’s PhysioMimix OOC System.

Richardson has seen an upward trend in acceptance following the FDA Modernization Act 2.0 and increased 3R project funding. This trend reflects a growing awareness that ethical considerations can be addressed while practical benefits are pursued, benefits such as lower workflow costs, higher efficiency, and faster clinical translation. The company participates actively in regulatory and standards groups, including the Critical Path Institute, the European Committee for Electrotechnical Standardization, and the IQ-MPS affiliate of the International Consortium for Innovation and Quality in Pharmaceutical Development.

“A growing body of evidence proves that the approach is more predictive than traditional methods and that technologies are being used in a complementary manner,” Richardson declares. “Standardization, a crucial area, needs to be addressed. Existing models will become more comprehensive, and the breadth of models and applications will expand along with more automation solutions.”

Together, these developments reflect a growing consensus: the future of preclinical research lies in a balanced ecosystem where animal models and NAMs work synergistically to improve human relevance, ethical standards, and translational outcomes.

View the full article here.

Emily USE THIS ONE | transition from in vivo models to NAMs

Dr. Emily Richardson

Lead Scientist (Toxicology)

Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix® lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.
    View full article

    Tag iconBioavailability,  Clinical translatability,  Toxicology

    Speak to our experts

    Request a meeting with one of our OOC experts to see how our products and services can support your studies

    Request a meeting

    Footer

    CN Bio logo

    332 Cambridge Science Park, Milton Road
    Cambridge, CB4 0WN

    UK: +44 (0) 1223 737 941

    US: +1 415 523 4005

    Privacy | Cookies | Regulatory | Accessibility
    Website terms | Terms of sale

    Product Recycling

    ©2025 CN Bio Innovations Ltd
    Registered No. ‍06517359. VAT No. GB978184563

    Latest news

    • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
    • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
    • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
    Cyber Essentials Logo